A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients.
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Anagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2012 New trial record